NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer
NovaBridge Biosciences (NBP) has announced the appointment of Chuck Silberstein as its new Chief Financial Officer, effective November 2, 2026. Silberstein succeeds Kyler Lei in the role. Silberstein brings extensive leadership experience to the company, having previously served as Co-Founder and CEO of FytonBio. His professional background also includes roles as CFO at GentiBio and serving as both CFO and Head of Business Development at the formerly Nasdaq-listed Applied Therapeutics.
Tickers: $APLT
Topics: CFO appointment leadership change